Source-grounded facts extracted from Xenon Pharmaceuticals Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Xenon Pharmaceuticals Inc. shareholders approved Proposal Six – Remuneration of Auditor at the 2026-06-02 meeting.
“Proposal Six – Remuneration of Auditor. The authority of the audit committee of the Board to set the remuneration of the auditor for the ensuing year was approved as follows: For Against Abstain Broker Non-Votes 90,370,029.64 2,369.65 27,237.00 0.00”
Xenon Pharmaceuticals Inc. shareholders approved Proposal Five – Appointment of Auditor at the 2026-06-02 meeting.
“Proposal Five – Appointment of Auditor. The appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the ensuing year was approved as follows: For Withheld Broker Non-Votes 90,371,967.64 27,668.65 0.00”
Xenon Pharmaceuticals Inc. shareholders approved Proposal Four – 2026 Equity Incentive Plan at the 2026-06-02 meeting.
“Proposal Four – 2026 Equity Incentive Plan. The Company's 2026 Equity Incentive Plan was approved as follows: For Against Abstain Broker Non-Votes 58,579,810.00 27,570,443.18 842,250.00 3,407,133.11”
Xenon Pharmaceuticals Inc. shareholders approved Proposal Three – Advisory Vote on Frequency of Say-on-Pay at the 2026-06-02 meeting.
“Proposal Three – Advisory Vote on Frequency of Say-on-Pay. The frequency of advisory votes on the compensation of the Company’s named executive officers, on an advisory basis, was approved as follows: 1 Year 2 Year 3 Year Abstain Broker Non-Votes 86,918,084.18 2,360.00 43,281.00 28,778.00 3,407,133.11”
Xenon Pharmaceuticals Inc. shareholders approved Proposal Two – Advisory Vote on Compensation of Named Executive Officers ("Say-on-Pay") at the 2026-06-02 meeting.
“Proposal Two – Advisory Vote on Compensation of Named Executive Officers (“Say-on-Pay”). The compensation of the Company’s named executive officers, on an advisory basis, was approved as follows: For Against Abstain Broker Non-Votes 82,156,320.53 4,769,025.65 67,157.00 3,407,133.11”
Xenon Pharmaceuticals Inc. shareholders approved Proposal One – Election of Directors at the 2026-06-02 meeting.
“Proposal One – Election of Directors . The following nominees were elected as directors to serve until the 2027 annual meeting of shareholders or until their respective successors are duly elected and qualified: For Against Broker Non-Votes Dawn Svoronos 82,475,281.53 4,517,221.65 3,407,133.11 Gillian Cannon 84,844,120.53 2,148,382.65 3,407,133.11 Steven Gannon 86,149,107.53 843,395.65 3,407,133.11 Elizabeth Garofalo 84,808,573.53 2,183,929.65 3,407,133.11 Justin Gover 86,290,281.53 702,221.65 3,407,133.11 Patrick Machado 86,603,916.53 388,586.65 3,407,133.11 Ian Mortimer 86,524,582.53 467,920.65 3,407,133.11 Gary Patou 86,114,511.53 877,991.65 3,407,133.11”
Xenon Pharmaceuticals Inc. reported financial results for the three months ended March 31, 2026.
“On May 7, 2026, Xenon Pharmaceuticals Inc. (the “Company”) announced via press release the Company’s financial results for the three months ended March 31, 2026.”
Xenon Pharmaceuticals Inc. engaged PricewaterhouseCoopers LLP as its auditor.
“On March 3, 2025, the Audit Committee approved the engagement of PricewaterhouseCoopers LLP (“PwC”) as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025.”
Xenon Pharmaceuticals Inc. dismissed KPMG LLP as its auditor.
“On March 3, 2025, the Audit Committee (the “Audit Committee”) of the Board of Directors of Xenon Pharmaceuticals Inc. (the “Company”) dismissed KPMG LLP (“KPMG”) as the Company’s independent registered public accounting firm.”
Sherry Aulin resigned as Chief Financial Officer at Xenon Pharmaceuticals Inc..
“On February 24, 2025, Ms. Sherry Aulin notified the Company of her decision to resign as Chief Financial Officer, effective June 30, 2025, for personal reasons.”
Christopher Von Seggern departed as Chief Commercial Officer at Xenon Pharmaceuticals Inc..
“On January 17, 2025, Christopher Von Seggern ceased to be the Chief Commercial Officer of Xenon Pharmaceuticals Inc. (the “Company”) and departed the Company as of such date.”
Xenon Pharmaceuticals Inc. reported financial results for the first quarter ended March 31, 2024.
“On May 9, 2024, Xenon Pharmaceuticals Inc. (the “Company”) announced via press release the Company’s financial results for the three months ended March 31, 2024.”
Mohammad Azab departed as Member of the Board at Xenon Pharmaceuticals Inc..
“On April 15, 2024, Dr. Simon Pimstone, chair of the board of directors (the “Board”) of Xenon Pharmaceuticals Inc. (the “Company”), and Dr. Mohammad Azab, a member of the Board, each informed the Company of their respective decisions not to stand for re-election to the Board at the Company’s 2024 annual meeting of shareholders (the “AGM”).”
Simon Pimstone departed as Chair of the Board at Xenon Pharmaceuticals Inc..
“On April 15, 2024, Dr. Simon Pimstone, chair of the board of directors (the “Board”) of Xenon Pharmaceuticals Inc. (the “Company”), and Dr. Mohammad Azab, a member of the Board, each informed the Company of their respective decisions not to stand for re-election to the Board at the Company’s 2024 annual meeting of shareholders (the “AGM”).”
Xenon Pharmaceuticals Inc. reported financial results for the fourth quarter and full year ended December 31, 2023.
“Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today reported financial results for the fourth quarter and full year ended December 31, 2023 and provided a corporate update.”
Xenon Pharmaceuticals Inc. reported the third quarter ended September 30, 2023 results: revenue No revenue was recognized.
“Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today reported financial results for the third quarter ended September 30, 2023”
Xenon Pharmaceuticals Inc. reported financial results for three and six months ended June 30, 2023.
“On August 9, 2023, Xenon Pharmaceuticals Inc. (the "Company") announced via press release the Company's financial results for the three and six months ended June 30, 2023.”
Mr. Justin Gover was appointed as director at Xenon Pharmaceuticals Inc..
“appointed Dr. Gillian Cannon and Mr. Justin Gover as directors of the Company, effective as of August 8, 2023.”
Dr. Gillian Cannon was appointed as director at Xenon Pharmaceuticals Inc..
“appointed Dr. Gillian Cannon and Mr. Justin Gover as directors of the Company, effective as of August 8, 2023.”
Xenon Pharmaceuticals Inc. shareholders approved Remuneration of Auditor at the 2023-06-01 meeting.
“The authority of the audit committee of the Board to set the remuneration of the auditor for the ensuing year was approved as follows: For Against Abstain Broker Non-Votes 50,683,345 284,460 2,832 1,827,721”
Xenon Pharmaceuticals Inc. shareholders approved Appointment of Auditor at the 2023-06-01 meeting.
“The appointment of KPMG LLP as the Company’s independent registered public accounting firm for the ensuing year was approved as follows: For Withheld Broker Non-Votes 51,532,487 1,265,871 0”
Xenon Pharmaceuticals Inc. shareholders approved Advisory Vote on Compensation of Named Executive Officers (Say-on-Pay) at the 2023-06-01 meeting.
“The compensation of the Company’s named executive officers, on an advisory basis, was approved as follows: For Against Abstain Broker Non-Votes 44,167,661 6,700,364 3,320 1,927,013”
Xenon Pharmaceuticals Inc. shareholders approved Election of Directors at the 2023-06-01 meeting.
“The following nominees were elected as directors to serve until the 2024 annual meeting of shareholders or until their respective successors are duly elected and qualified: For Against Broker Non-Votes Simon Pimstone 49,766,312 1,105,033 1,927,013 Dawn Svoronos 50,657,151 214,194 1,927,013 Mohammad Azab 49,442,996 1,428,349 1,927,013 Steven Gannon 50,683,492 187,853 1,927,013 Elizabeth Garofalo 50,657,402 213,943 1,927,013 Patrick Machado 48,515,986 2,355,359 1,927,013 Ian Mortimer 50,663,448 207,897 1,927,013 Gary Patou 48,629,611 2,241,734 1,927,013”
Xenon Pharmaceuticals Inc. reported financial results for the first quarter ended March 31, 2023.
“the Company’s financial results for the three months ended March 31, 2023”
Xenon Pharmaceuticals Inc. reported financial results for the year ended December 31, 2022.
“On March 1, 2023, Xenon Pharmaceuticals Inc. (the “Company”) announced via press release the Company’s financial results for the year ended December 31, 2022.”
Xenon Pharmaceuticals Inc. reported financial results for the third quarter ended September 30, 2022.
“On November 8, 2022, Xenon Pharmaceuticals Inc. (the “Company”) announced via press release the Company’s financial results for the six and nine months ended September 30, 2022.”
Simon N. Pimstone was appointed as Chair of the Board at Xenon Pharmaceuticals Inc..
“appointed Dr. Pimstone, current Executive Chair of the Board, as Chair of the Board, effective upon and subject to his re-election as a director at the Annual Meeting.”
Michael Hayden departed as Director at Xenon Pharmaceuticals Inc..
“Michael Hayden, notified the Board that he would not stand for re-election as a director of the Board at the Annual Meeting.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.